Histiocytic disorders are rare conditions where certain immune cells (called histiocytes) build up in different parts of the body, causing inflammation and organ damage. Examples include Langerhans cell histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, Juvenile Xanthogranuloma, and hemophagocytic lymphohistiocytosis.
This study does not test a new drug. Instead, it focuses on learning more about the biology of these diseases. Researchers will collect samples, such as blood, tissue from biopsies, cerebrospinal fluid, or saliva from routine medical procedures. These samples will be analyzed to study genes, proteins, and biomarkers that may help doctors diagnose these conditions earlier and develop better treatments in the future.
The study is part of the North American Consortium for Histiocytosis (NACHO) and works alongside NACHO clinical trials. Biomarker discovery is a key goal, which could lead to new diagnostic tools or therapies.
Eligibility
Children and adults of any age
Known or suspected histiocytic disorder, including Langerhans cell histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, Juvenile Xanthogranuloma, hemophagocytic lymphohistiocytosis, or other rare histiocytic disorders
Patients and family members at NACHO institutions
To inquire about this trial, fill out our online referral form:
